Aethlon Medical, Inc.
AEMD · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.17 | 0.31 | -2.00 |
| FCF Yield | -171.27% | -29.85% | -18.33% | -5.87% |
| EV / EBITDA | 0.03 | -2.56 | -4.21 | -15.16 |
| Quality | ||||
| ROIC | -161.80% | -188.42% | -73.12% | -58.81% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.57 | 0.83 | 0.87 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -4.49% | -23.23% |
| Free Cash Flow Growth | 26.35% | 9.33% | -13.17% | -48.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | 0.38 | 1.14 | 1.59 |
| Interest Coverage | -924.06 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -574.57 | -790.74 | 0.00 | 158.78 |